New Technology for Prostate Cancer

In this multi-method research study, we will evaluate how patients and providers understand and incorporate new risk assessment technologies into clinical decisions for prostate cancer. First, using population-level administrative claims data, we will define contemporary adoption patterns and study the association of prostate MRI and/or genomic testing with the initial management received by the patient. Then, to understand how both patients and providers perceive of these technologies in the process of decision-making, we will conduct in-depth, semi-structured qualitative interviews of patients with prostate cancer, as well as physicians who treat prostate cancer.

Funding source: National Institutes of Health (National Cancer Institute)

Principal Investigator: Michael Leapman